Table 3

The cost, quality adjusted life years, transmission to partners, PID cases and overtreatment in standard care compared to point of care tests for chlamydia and gonorrhoea in genitourinary medicine clinics in the UK: baseline and scenario analyses results.

Scenario	Baseline	1 Short time to treat	2 Low prevalence	3 No PID or onward transmission	4 High POC NAAT test cost	5 Wait for test anxiety
Scenario	See tables 1 and 2 for full baseline parameter list	Rx time=4 days (baseline: 10 days)	CT=4.3% M, 3.7% F NG=1.3% M, 0.5% F (baseline: CT=8.6% M, 7.4% F, NG=2.5% M, 0.9% F)	Transmission probability 0% for CT/NG, PID=0 (baseline: 5% CT, 10% NG per unprotected act, PID=0.00035 per day)	POC NAAT test cost=£29.73 (baseline £19.73)	Utility post-test status unknown=0.95 (baseline: 1)
SC
Cost	£115 627 887	£115 613 353	£112 997 661	£115 595 915	£115 627 887	£115 627 887
QALY	184 012	184 013	184 036	184 015	184 012	181 523
Transmissions	17 561	7434	8811	–	17 561	17 561
PID	223	132	119	–	223	223
Overtreatment	95 382	95 382	100 278	95 431	95 382	95 382
POC
Cost	£103 873 872	£103 873 872	£101 452 506	£103 868 307	£116 078 901	£103 873 872
QALY	184 059	184 059	184 084	184 059	184 059	184 059
Transmissions	–	–	–	–	–	–
PID	34	34	17	–	34	34
Overtreatment	–	–	–	–	–	–
Difference (POC-SC)
Cost	−£11 754 015	−£11 739 481	−£11 545 155	−£11 727 608	£451 014	−£11 754 015
QALY	46	45	48	44	46	2536
Transmissions	−17 561	−7434	−8811	0	−17 561	−17 561
PID	−189	−98	−102	0	−189	−189
Overtreatment	−95 382	−95 382	−100 278	−95 431	−95 382	−95 382

CT, Chlamydia trachomatis, NAAT, nucleic acid amplification test; NG, Neisseria gonorrhoea, PID, pelvic inflammatory disease, POC, point of care; QALY, quality adjusted life year; Rx, treatment; SC, standard care.